GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Loans Receivable

Context Therapeutics (FRA:6K9) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Loans Receivable?

Context Therapeutics's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Context Therapeutics Loans Receivable Historical Data

The historical data trend for Context Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Loans Receivable Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
- - - - -

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Context Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Context Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics (FRA:6K9) Business Description

Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines